Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $63.25.

A number of analysts have recently commented on SUPN shares. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a report on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price on the stock. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $40.00 to $65.00 in a report on Thursday, October 9th. Finally, Zacks Research downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th.

Insider Buying and Selling

In other news, CEO Jack A. Khattar sold 59,900 shares of the stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at approximately $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 116,235 shares of company stock valued at $5,694,447 over the last 90 days. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at about $1,434,000. CIBC Bancorp USA Inc. purchased a new position in Supernus Pharmaceuticals in the third quarter worth about $275,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Supernus Pharmaceuticals in the third quarter worth approximately $1,872,000. Caxton Associates LLP purchased a new stake in shares of Supernus Pharmaceuticals during the third quarter valued at approximately $1,117,000. Finally, Woodline Partners LP increased its position in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $48.32 on Wednesday. The firm has a market capitalization of $2.77 billion, a P/E ratio of -142.11, a P/E/G ratio of 0.57 and a beta of 0.71. The stock has a 50 day moving average price of $48.21 and a 200-day moving average price of $42.14. Supernus Pharmaceuticals has a 52-week low of $29.16 and a 52-week high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.Supernus Pharmaceuticals’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.69 earnings per share. On average, equities analysts forecast that Supernus Pharmaceuticals will post 2.38 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.